GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vincerx Pharma Inc (NAS:VINC) » Definitions » EV-to-EBITDA

Vincerx Pharma (Vincerx Pharma) EV-to-EBITDA : -0.52 (As of May. 24, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vincerx Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vincerx Pharma's enterprise value is $17.78 Mil. Vincerx Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-33.96 Mil. Therefore, Vincerx Pharma's EV-to-EBITDA for today is -0.52.

The historical rank and industry rank for Vincerx Pharma's EV-to-EBITDA or its related term are showing as below:

VINC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.26   Med: 0   Max: 1.09
Current: -0.52

During the past 5 years, the highest EV-to-EBITDA of Vincerx Pharma was 1.09. The lowest was -3.26. And the median was 0.00.

VINC's EV-to-EBITDA is ranked worse than
100% of 448 companies
in the Biotechnology industry
Industry Median: 10.08 vs VINC: -0.52

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-24), Vincerx Pharma's stock price is $0.7036. Vincerx Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.790. Therefore, Vincerx Pharma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Vincerx Pharma EV-to-EBITDA Historical Data

The historical data trend for Vincerx Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vincerx Pharma EV-to-EBITDA Chart

Vincerx Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- -21.53 -1.72 0.40 -0.36

Vincerx Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 -0.06 -0.07 -0.36 -3.11

Competitive Comparison of Vincerx Pharma's EV-to-EBITDA

For the Biotechnology subindustry, Vincerx Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vincerx Pharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vincerx Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vincerx Pharma's EV-to-EBITDA falls into.



Vincerx Pharma EV-to-EBITDA Calculation

Vincerx Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=17.783/-33.963
=-0.52

Vincerx Pharma's current Enterprise Value is $17.78 Mil.
Vincerx Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vincerx Pharma  (NAS:VINC) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Vincerx Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.7036/-1.790
=At Loss

Vincerx Pharma's share price for today is $0.7036.
Vincerx Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.790.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Vincerx Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vincerx Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Vincerx Pharma (Vincerx Pharma) Business Description

Traded in Other Exchanges
N/A
Address
260 Sheridan Avenue, Suite 400, Palo Alto, CA, USA, 94306
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses to develop, use, manufacture, commercialize, sublicense and distribute a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation ADC platform.
Executives
Alexander A. Seelenberger officer: Chief Financial Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Raquel E. Izumi director, 10 percent owner, officer: Chief Operations Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Ahmed Md Hamdy director, 10 percent owner, officer: President and CEO 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Tom C Thomas officer: See Remarks 180 LOMA ALTRO, C/O MOCON INC, LOS GATOS CA 95030
Christopher P. Lowe director 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Laura I. Bushnell director 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
David Efraim Rosen 10 percent owner 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Sooin Hwang officer: Chief Business Officer 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Xiaoming Zhang officer: Chief Technology Officer 260 SHERIDAN AVE, SUITE 400, PALO ALTO CA 94306
Ruth E. Stevens director 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Garban Hermes De Jesus officer: Chief Medical Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
John C. Byrd 10 percent owner 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Brian Druker director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
John H. Lee director 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054

Vincerx Pharma (Vincerx Pharma) Headlines

From GuruFocus

Vincerx Pharma Provides Key Strategic Update

By GuruFocusNews GuruFocusNews 07-06-2022

Vincerx Pharma Provides Key Strategic Update

By GuruFocusNews GuruFocusNews 06-16-2022